FOCUS ON FELBAMATE - BEGINNING A NEW-GENERATION OF ANTICONVULSANT AGENTS FOR THE TREATMENT OF EPILEPSY

Authors
PONZILLO JJ MALKOFF MD
Citation
Jj. Ponzillo et Md. Malkoff, FOCUS ON FELBAMATE - BEGINNING A NEW-GENERATION OF ANTICONVULSANT AGENTS FOR THE TREATMENT OF EPILEPSY, Hospital formulary, 28(10), 1993, pp. 837
Citations number
NO
Categorie Soggetti
Pharmacology & Pharmacy
Journal title
Hospital formulary
ISSN journal
00986909 → ACNP
Volume
28
Issue
10
Year of publication
1993
Database
ISI
SICI code
Abstract
Felbamate is the first new drug approved by the FDA for the treatment of epilepsy since valproic acid in 1978. Felbamate is indicated for th e treatment of partial seizures in adults and Lennox-Gastaut syndrome in children. Results of clinical trials indicate that felbamate decrea ses seizure frequency in patients with partial seizures. The drug appe ars to have a more favorable side effect profile than currently availa ble drugs. Felbamate is a welcome addition to the pharmacologic armame ntarium for the treatment of epilepsy.